

Andelyn Biosciences Launches LVV Curator Platform To Accelerate Lentiviral Manufacturing From Discovery To Clinic

May 13, 2026 | News

New standardized LVV manufacturing platform extends the proven Curator® methodology beyond AAV programs, helping cell therapy developers reduce development timelines, improve scalability, and strengthen GMP and regulatory readiness.



New platform leverages the established Curator® platform methodology to industrialize Lentivirus processes from concept to clinic.

[Andelyn Biosciences](#), a leading cell and gene therapy contract development and manufacturing organization (CDMO), announced the launch of its [LVV Curator® Platform](#), a standardized lentiviral vector (LVV) manufacturing solution built on the same proven modular approach that supports clinical and commercial adeno-associated virus (AAV) programs.

The LVV Curator Platform, Andelyn's most recent addition to its Curator line of viral vector platforms, addresses a major challenge in cell therapy development: transitioning from research-grade methods to GMP manufacturing. By offering a predefined, scalable manufacturing framework, the platform reduces development time, lowers costs, and facilitates high productivity and purity.

"Developers should not have to choose between speed and quality when advancing lentiviral programs," said Wade Macedone, CEO at Andelyn Biosciences. "With LVV Curator, we are bringing the same platform discipline under the same quality systems that power our commercial AAV manufacturing to LVV, enabling sponsors to advance their therapies with greater confidence from the start."

Key highlights of the LVV Curator Platform:

- **Platform Pedigree with Proven Track Record**

Built on the Curator Platform methodology that has supported over 100 AAV programs, offering a structured and repeatable framework that minimizes development risk.

- **From AAV History to LVV Credibility**

Extends a commercially validated platform approach into lentiviral vector manufacturing, bringing consistency, scalability, and operational discipline to early-stage LVV programs.

- **Early Partnership Model with Optimization-by-Design™**

Collaborative development beginning at project initiation, including design of experiments (DOE) and data-driven process optimization to establish robust processes faster.

- **Legacy Curator HEK293 Cell Line with Regulatory Acceptance**

Uses a clinically validated HEK293 cell line with established regulatory acceptance, helping to streamline development and build regulatory confidence.

- **Quality-First Development Approach**

Processes are designed with GMP requirements in mind from the outset, supported by unified cGMP quality systems aligned with commercial manufacturing standards.

- **Flexible Platform Methodology**

Allows for the seamless integration of client-specific cell lines while leveraging the standardized process controls and analytical rigor of the Curator methodology.

The LVV Curator Platform is designed to support early-phase programs with a focus on speed, reproducibility, and regulatory readiness, while maintaining a clear path to future scale-up.

“By combining a proven platform foundation with a flexible, partnership-driven business model, we are helping innovators bridge the gap from discovery to clinical manufacturing more efficiently,” added Matt Niloff, CCO at Andelyn Biosciences.

The launch of LVV Curator reinforces Andelyn Biosciences’ commitment to enabling next-generation gene therapies through platform-driven development and manufacturing solutions.

The LVV Curator Platform is now available to new and existing clients.